Trial Profile
Alemtuzumab for induction immunosuppression in elderly renal transplant recipients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Anti-interleukin-2 receptor monoclonal antibody
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 19 Aug 2015 New trial record